Pfizer Inc has announced it has entered into an agreement to acquire PowderMed Ltd, an Oxford-based company specializing in the emerging science of DNA-based vaccines. PowderMed has developed a unique and proprietary technology to deliver DNA directly to the cells of the body’s immune system and is advancing a promising pipeline of proprietary vaccine candidates for influenza and chronic viral diseases.
Existing investors including Softbank and Lakestar reinvest in the tourism booking platform
Andera has reinvested and Prenax has acquired LM Information's subscription management business
Sale ends a six-year holding period for KCP, which backed the company with a £3.3m investment
Danish internet company could reportedly be listed at a valuation of $1bn